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Abstract
Objective:  Clinical  Pharmacy  Services  (CPS)  are  considered  standard  of  care  and  is  endorsed
by the  Joint  Commission  International,  the  American  Academy  of  Pediatrics,  and  the  American
College of  Clinical  Pharmacy.  In  Brazil,  single  experiences  have  been  discreetly  arising  and  the
importance  of  these  services  to  children  and  adolescents  care  has  led  to  interesting  results,
but certainly  are  under  reported.  This  short  report  aims  to  discuss  the  effect  of  implementing
a bedside  CPS  at  a  Brazilian  Pediatric  Intensive  Care  Unit  (PICU).
Methods:  This  is  a  cross-sectional  study  conducted  in  a  12  bed  PICU  community  hospital,  from
Campo Largo/Brazil.  Subjects  with  <18  years  old  admitted  to  PICU  were  included  for  descriptive
analysis  if  received  a  CPS  intervention.
Results:  Of  53  patients  accompanied,  we  detected  141  preventable  drug-related  problems
(DRPs) which  were  solved  within  clinicians  (89%  acceptance  of  all  interventions).  The  most
common interventions  performed  to  improve  drug  therapy  included:  preventing  incompatible
intravenous  solutions  (21%)  and  a  composite  of  inadequate  doses  (17%  due  to  low,  high  and
non-optimized  doses).  Among  the  top  ten  medications  associated  with  DRPs,  ﬁve  were  antimi-
crobials. By  analyzing  the  correlation  between  DRPs  and  PICU  length  of  stay,  we  found  that  74%
of all  variations  on  length  of  stay  were  associated  with  the  number  of  DRPs.
Conclusions:  Adverse  drug  reactions  due  to  avoidable  DRPs  can  be  prevented  by  CPS  in  a  mul-
tifaceted  collaboration  with  other  health  care  professionals,  who  should  attempt  to  use  active
and evidence-based  strategies  to  reduce  morbidity  related  to  medications.
© 2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY  license  (http://creativecommons.org/licenses/by/4.0/).∗ Corresponding author.
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license (http://creativecommons.org/licenses/by/4.0/).
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Unidades  de  Cuidados  Intensivos  Pediátricos
Resumo
Objetivo:  Servic¸os  de  Farmácia  Clínica  (SFC)  são  considerados  um  padrão  de  atendimento  à
saúde e  são  endossados  pela  Joint  Commission  International,  a  American  Academy  of  Pedi-
atrics, e  a  American  College  of  Clinical  Pharmacy.  No  Brasil,  experiências  isoladas  vêm  surgindo
discretamente  e  a  importância  desses  servic¸os  para  o  cuidado  de  crianc¸as  e  adolescentes  têm
levado a  resultados  interessantes,  mas  que  certamente  são  sub-relatados.  Este  artigoório  tem
como objetivo  discutir  o  efeito  da  implantac¸ão  de  um  SFC  à  beira  do  leito  em  uma  Unidade  de
Cuidados Intensivos  Pediátricos  (UCIP)  brasileira.
Métodos:  Esse  é  um  estudo  transversal,  realizado  em  uma  UCIP  de  hospital  da  comunidade  com
12 leitos,  em  Campo  Largo,  Brasil.  Foram  incluídos  indivíduos  com  <18  anos  internados  em  UCIP
para análise  descritiva,  quando  receberam  uma  intervenc¸ão  do  SFC.
Resultados:  De  53  pacientes  acompanhados,  foram  detectados  141  Problemas  Relacionados
a Medicamentos  (PRM)  evitáveis  que  foram  resolvidos  em  conjunto  com  os  médicos  (89%  de
aceitac¸ão de  todas  as  intervenc¸ões).  As  intervenc¸ões  mais  comuns  para  melhorar  a  terapia
medicamentosa  foram:  prevenc¸ão  de  soluc¸ões  intravenosas  incompatíveis  (21%)  e  doses  inade-
quadas (17%  devido  a  doses  baixa,  alta  e  não  otimizadas).  Entre  os  dez  principais  medicamentos
associados  à  PRM,  cinco  eram  antimicrobianos.  Ao  analisar  a  correlac¸ão  entre  o  PRM  e  tempo
de permanência  na  UCIP,  veriﬁcamos  que  74%  de  todas  as  variac¸ões  no  tempo  de  permanência
eram associadas  com  o  número  de  PRM.
Conclusões:  Reac¸ões  adversas  a  medicamentos  devido  a  PRM  evitáveis  podem  ser  prevenidas
por SFC  em  uma  colaborac¸ão  multifacetada  com  outros  proﬁssionais  de  saúde.  Tais  problemas
podem ser  evitados  por  meio  de  estratégias  ativas  e  baseadas  em  evidências  para  reduzir  a
morbidade  relacionada  a  medicamentos.
© 2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Este e´ um
artigo Open  Access  sob  uma  licenc¸a  CC  BY  (http://creativecommons.org/licenses/by/4.0/).
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computerized  physician  order  entry,  where  all  clinical  doc-ntroduction
he  increasing  number  of  medications  being  approved  to
dults  with  potential  use  on  Pediatrics,1 the  need  to  treat
linically  challenging  diseases,  and  the  ethical  issues  sur-
ounding  pediatrics  research  put  children  and  adolescents
t  more  risks  associated  to  medication  adverse  events.2,3 To
llustrate  this  scenario,  a  nested-cohort  study  conducted  by
ellis  and  colleagues2 demonstrated  that  unapproved  pre-
criptions  were  associated  with  an  augmented  hazard  of
aving  an  adverse  event  (hazard  ratio  1.30,  95%CI  1.20--1.30,
<0.001).
To  detect  medication  adverse  reactions  and  to  avoid  pre-
entable  drug-related  problems  (DRPs),  many  accredited
ospitals4--7 have  been  putting  efforts  to  implement  Clin-
cal  Pharmacy  Services  (CPS).  Since  the  last  decade,  the
ultifaceted  collaboration  between  Pediatricians,  Critical
are  Physicians  and  Clinical  Pharmacists  was  endorsed  by
he  American  Academy  of  Pediatrics,5 American  College  of
linical  Pharmacy  and  many  studies  in  the  ﬁeld.5--9
Despite  the  well-stablished  importance5--9 of  CPS  to  chil-
ren  and  adolescents,  in  the  last  years,  Brazil  has  started
he  implementation  of  single  experiences  around  the  coun-
ry,  especially  for  PICU  patients,  which  has  led  to  interesting
ut  under  reported  results.This  study  is  endorsed  by  the  evolving  role  of  CPS
n  Brazil,  which  has  been  due  to  the  recent  approval
f  a  legislation  about  clinical  activities  developed  by
u
a
bharmacists10; and  the  increasing  interest  of  Latin  Amer-
can  health  institutions  to  get  accredited.11 Noteworthy,
ccreditation  Organizations,  such  as  the  Joint  Commission
nternational,  advocates  that  strategies  to  prevent  medi-
ation  errors,  likewise  pharmacists-driven  clinical  services,
hould  be  implemented  to  reduce  the  number  of  drug-
elated  undesired  events.12
The  aim  of  this  short  report  is  to  describe  the  implemen-
ation  and  results  of  a  CPS  directed  to  PICU  inpatients  in  a
razilian  setting.
ethod
his  study  complies  with  Helsinki’s  Declaration  and  was
pproved  by  the  Local  Ethics  Committee.
In  one  12-bed  community’s  hospital  PICU  located  in
ampo  Largo,  Brazil,  we  started  the  implementation  of  a
PS  in  2012,  due  to  accreditation  processes  and  Clinical
irector  incentives  to  improve  local  health  assistance.  The
forementioned  hospital  attends  all  critically  ill  children
ho  live  approximately  200km  distance  from  Curitiba  (the
iggest  city  in  Paraná  State,  southern  Brazil).  Some  of  the
ain  features  of  such  hospital  include:  the  presence  of  amentations  and  prescriptions  are  electronically  registered
nd  can  be  remotely  monitored  by  an  online  system;  and,
y  the  time  of  the  study,  one  part-time  pharmacist  was
cy  Services  399
Table  1  Patients’  characteristics.
Characteristics  n  (%)
Number  of  included  patients  35
Age in  years  1.50  (0.35--3.25)
Male 22  (63)
Diagnostic  at  admission  (ICD-10)
Infectious  diseases  4  (11)
Neurologic  system  disorders  4  (11)
Respiratory  system  disorders  20  (57)
Digestive  system  disorders  4  (11)
Co-morbidities  during  hospital  stay
(International  Classiﬁcation  of  Diseases-10)
Endocrine  or  metabolic  disorders  4
Neurologic  system  disorders  6
Circulatory  system  disorders  4
Respiratory  system  disorders  10
Number  of  drug-related  problems  141
Mechanical  ventilation  11  (31)
Use of  artiﬁcial  nutrition  28  (80)
Use of  vasoactive  drugs  12  (34)
Use of  formulary  restricted
antimicrobial  therapy
15  (43)
Intensive  care  lenght  of  stay  in  days  18  (8.50--38.25)
Unless otherwise stated, all variables are expressed as absolute
and/or relative (%) values. Artiﬁcial nutrition includes par-
enteral and enteral nutrition.
All continuous variables were described as median and inter-
quartile range.
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responsible  to  provide  CPS  to  inpatients  (PICU  and  30  bed
general  pediatric  wards).
The  CPS  consisted  in  a  systematic  service  dedicated
to:  participating  in  clinical  rounds,  elaborating  institu-
tional  protocols,  antiepileptic  Therapeutic  Drug  Monitoring
(TDM),  reviewing  each  of  prescribed  drug  dosages,  indica-
tions,  duration  of  treatments,  drug  interactions,  relative
and  absolute  contraindications  and  intravenous  drug  incom-
patibilities.
We  sought  to  retrospectively  analyze  the  demographics
(age  and  sex)  and  clinical  variables  (cause  of  admission,
comorbidities,  use  of  vasoactive  drugs,  use  of  mechanical
ventilation,  use  of  artiﬁcial  nutrition,  use  of  antimicrobial
therapy  and  PICU  length  of  stay).  The  prevalence  and  types
of  DRPs  found  in  such  vulnerable  population  attended  by  the
CPS  during  the  implementation  phase  (May,  October  2012)
were  also  reported.
DRPs  are  deﬁned  as  all  situations  that  predisposed
patients  of  not  having  optimized  drug  therapy,  such  as:
intravenous  solutions  instability  and  incompatibility,  wrong
infusion  time,  high  or  low  doses  according  to  literature,  need
to  adjust  a  dose  according  to  renal  clearance  or  TDM  (serum
concentrations  of  selected  drugs),  presence  of  duplicated
drug  therapy  and  wrong  pharmaceutical  form.  Finally,  we
assessed  the  acceptance  of  our  service  by  quantifying  the
acceptability  of  CPS  interventions  by  physicians  and  nursing
team.
Our  conventional  sample  was  calculated  based  on  a
5%  alfa,  80%  power  and  r=0.50  as  statistically  signiﬁcant
correlation  for  this  exploratory  analysis,  which  led  to  29
patients.13 An  exploratory  univariable  analysis  (two-tailed,
Spearman  rho)  was  performed  to  assess  the  association
between  DRPs  and  PICU  length  of  stay.  All  tests  were
two-sided  and  p<0.05  was  set  as  null  hypothesis  rejec-
tion.  Descriptive  statistics  applied  to  all  patients  with  DRPs.
The  aforementioned  covariates  were  reported  as  median
and  interquartile  intervals,  and  dichotomous  variables  were
reported  as  absolute  and  relative  numbers  (%)  (Table  1).
Results
In  5 consecutive  months  of  implementation,  53  patients
were  accompanied  by  two  part-time  clinical  pharmacists
(5h/daily  dedication,  except  on  weekends).  18  patients
did  not  present  a  DRP,  so  they  were  not  included  in  the
descriptive  analysis.  We  found  141  DRPs  in  35  patients
(Tables  1  and  2),  who  were  likely  to  be  male  (63%)
and  were  1.50-years-old  in  average.  Most  of  them  were
admitted  due  to  respiratory  disorders,  such  as  acute
asthma,  bronchospasm  and  bronchiolitis-associated  respira-
tory  insufﬁciency.  One  third  (31.40%)  needed  mechanical
ventilation  during  PICU  stay,  and  34.30%  used  vasoactive
drugs  to  treat  hemodynamic  instability.
Out  of  the  141  DRPs  detected  by  CPS,  the  most
common  interventions  performed  to  improve  drug  ther-
apy  were:  preventing  incompatible  intravenous  solutions
(21%)  and  a  composite  of  inadequate  doses  (17%  due
to  low,  high  and  non-optimized  doses)  (Fig.  1).  Among
the  top  ten  medications  associated  with  DRPs,  ﬁve  were
antimicrobials:  meropenem,  vancomycin,  piperacillin  and
tazobactan,  cefepime  and  oseltamyvir  (Table  2).
b
w
w
pICD-10, International Classiﬁcation of Diseases Edition n. 10.
By  analyzing  the  Spearman-rho  correlation  between  DRPs
nd  PICU  length  of  stay,  we  found  that  74%  of  all  variations
n  PICU  length  of  stay  were  associated  with  the  detected
RPs.
iscussion
n  our  sample,  the  implementation  of  a  CPS  directed  at  PICU
npatients  has  shown  the  value  of  such  services  on  detecting
nd  solving  DRPs,  which  were  at  most  preventable  situations
hat  could  lead  to  unnecessary  morbidity.
Through  an  average  33  days  of  PICU  stay  (95%CI
0.22--46.38),  we  found  that  each  patient  could  be  exposed
o  as  much  as  2.6  DRPs,  and  interventions  toward  solv-
ng  them  were  highly  accepted  by  medical  and  nursing
eam  (89%  acceptability  rate).  Such  acceptance  of  inter-
entions  by  PICU  team  was  consistently  high,  as  already
emonstrated  before.8,11,12 The  message  behind  these  ﬁnd-
ngs  stands  for  a  good  CPS  implementation  process,  which
ad  as  determinants  of  success:  the  institutional  support
nd  communication  between  hospital’s  pharmacy  manager,
linical  director,  PICU  nurses  and  infectious  disease  team.
Still  on  DRPs  detected,  as  shown  in  Table  2,  sta-
ility  and  compatibility  problems  were  commonly  seem
ith  piperacillin  and  tazobactam.  Wrong  infusion  time
as  commonly  detected  with  fentanyl,  and  duplicated
harmacotherapy  was  more  prevalent  with  omeprazole
400  Okumura  LM  et  al.
Table  2  Common  drug-related  problems  in  pediatric  intensive  care.
Type  of  drug-related  problems  Number  (%)  of  drug-related  problems  involved  with  each  medication
Meropenem  Vancomycin  Piperacillin/tazobactam  Fentanyl  Cefepime  Omeprazole
Incompatibility  6  (4)  4  (2.70)  9  (6)  2  (1.30)  6  (4)  2  (1.30)
High dose  1  (0.60)  3  (2)  --  --  --  3  (2)
Renal dose  adjustment  1  (0.60)  1  (0.60)  --  1  (0.60)  1  (0.60)  --
Wrong infusion  time  --  1  (0.60)  --  3  (2)  --  --
Low dose  1  (0.60)  1  (0.60)  --  2  (1.30)  --  --
Therapeutic  drug  monitoring
dose  adjustment
--  --  --  --  --  --
Duplicated drugs -- -- -- -- -- 1  (0.60)
Wrong pharmaceutical  form 1  (0.60) -- -- -- -- 1  (0.60)
Total (%)  10  (6.80)  10  (6.80)  9  (6)  8  (5.30)  7  (4.70)  7  (4.70)
Type  of  drug-related  problems  Number  (%)  of  drug-related  problems  involved  with  each  medication  Other
Oseltamyvir  Captopril  Methyprednisolone  Phenobarbital
Incompatibility  --  --  1  (0.60)  --  24  (17)
High dose  --  1  (0.60)  3  (2)  1  (0.60)  10  (8)
Renal dose  adjustment  --  2  (1.30)  --  --  10  (8)
Wrong infusion  time  --  --  --  --  4  (3)
Low dose  --  1  (0.60)  --  --  7  (5)
Therapeutic drug  monitoring
dose  adjustment
--  --  --  2  (1.30)  7  (5)
Duplicated drugs --  --  --  --  4  (3)
Wrong pharmaceutical  form  5  (3.30)  --  --  --  4  (3)
Total (%) 5  (3.30)  4  (2.70)  4  (2.70)  3  (2)  74  (53)
Selected drugs accounts for 67 (47%) from 141 drug-related problems (DRP) found by pharmacists. Stability, compatibility and dose were
common problems identiﬁed by clinical pharmacists. ‘‘Others’’ column refers to drugs that were less common. Only drugs with more
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bthan 4 DRPs were reported.
intravenous  and  oral  routes  prescribed).  Sub-therapeutic
oses  of  phenobarbital  were  corrected  by  pharmacists,
ither  by  literature-based  information  or  by  TDM.
Few  studies8,14--17 were  already  published  in  PICU  sett-
ngs,  but  none  comes  from  Latin  American  countries.  A  single
andomized  controlled  trial8 assessed  the  effectiveness  of
PS  in  reducing  inpatient  length  of  stay.  An  observational
tudy  conducted  in  French-speaking  countries  described  966
nterventions  done  to  solve  DRP  in  270  patients,  through
 months  of  CPS  implementation.14 Other  researches  had
lso  showed  positive  results.  A  cohort  study  conducted  in
nited  States  included  1120  patients  and  found  that  half
f  patients  were  exposed  to  medication  errors.  They  found
hat  28%  of  all  problems  detected  were  related  to  dose,
nd  other  18%  with  wrong  route  of  administration.15 In
nited  Kingdom,  antibiotics  and  inotropes  were  reported
o  be  the  top  drugs  associated  with  medications  errors.16
ur  study  showed  similar  results  by  having  meropenen,
iperacillin  and  tazobactam,  vancomycin,  cefepime  and
seltamyvir  as  part  the  top  ten  medications  associated  to
RP.
Unfortunately,  some  studies16 did  not  specify  the  details
f  the  medication  errors  detected,  which  are  indispensable
or  PICU  pharmacists.  To  overcome  such  lack  of  descrip-
ive  information,  our  study  identiﬁed  that  weight  variation,
cute  kidney  injury  and  TDM  led  to  dose  adjustment
u
c
tnterventions,  namely:  vancomycin,  captopril  and  pheno-
arbital.
Our  research  was  not  free  of  limitations  and  some  of  them
eserve  special  attention.  At  ﬁrst,  confounders  are  inherent
o  cross-sectional  studies  and  some  of  the  assumptions  made
n  this  manuscript  should  be  further  investigated  in  larger
rospective  cohorts.  At  second,  because  it  was  not  part  of
ur  ﬁrst  objective,  we  did  not  provide  a  descriptive  charac-
erization  of  all  drugs  used  in  our  PICU.  On  the  other  hand,
e  focused  on:  (a)  clinical  description  of  the  population,
hich  is  important  to  physicians  and  clinical  pharmacists;
b)  the  main  DRPs  found,  which  is  of  special  interest  to
ther  settings  that  aim  to  implement  such  services.  At  third,
ur  casuistic  comprised  children  and  adolescents,  but  not
eonates,  who  are  subject  of  higher  risks  of  adverse  drug
eactions.18 Herein,  when  interpreting  our  results,  exter-
al  validity  of  our  data  should  be  carefully  interpreted,
iven  that  we  did  not  attend  trauma,  large  surgeries,  and
eoplasms.  In  addition,  the  univariate  analysis  should  be
nterpreted  carefully,  due  to  our  study’s  limitations.  On  the
ther  hand,  it  reinforces6,8,9 the  importance  of  monitor-
ng  long  term  critically  ill  inpatients,  given  that  DRPs  may
e  more  prevalent  in  this  population,  which  could  lead  to
ndesired  drug-related  events.  Lastly,  data  collection  is  a
ommon  drawback  from  retrospective  studies.  We  sought
o  reduce  such  problems  by  having  three  post-graduated
Relation  between  safe  use  of  medicines  and  Clinical  Pharmacy  S
Figure  1  Incompatibility  problems  avoided  by  Clinical  Phar-
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pharmacists  in  this  activity,  who  consulted  each  other  when
discrepancies/inconsistencies  were  found.
Every  ten  patients  admitted  to  PICU,  six  had  a  DRPs
detected  by  CPS  and  ﬁve  received  an  intervention  to  opti-
mize  drug  therapy.  PICU  setting  has  a  high  prevalence  of
compatibility  and  stability  DRPs  (Table  2),  and  dose  adjust-
ments  should  be  promptly  assessed  especially  on  inadequate
therapeutic  drug  serum  concentrations,  weight  changes  and
other  risk  factors  that  may  change  drug  distribution  and
excretion,  such  as  acute  kidney  injury.  Based  on  our  imple-
mentation  experience,  CPS  might  be  a  feasible  technology
that  improve  infants,  children  and  adolescents  care.  Pedia-
tricians’  and  stakeholders  should  attempt  to  prevent  DRPs  by
using  active  and  evidence-based  strategies  to  reduce  avoid-
able  morbidity-related  to  medications.4--6,8,9
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